| 1979 |
Two distinct acyl-CoA:glycine N-acyltransferases were purified to near-homogeneity from bovine liver mitochondria, each consisting of a single polypeptide chain (~33 kDa). Preliminary kinetic studies were consistent with a sequential (ordered) reaction mechanism in which acyl-CoA binds first, glycine adds before CoA leaves, and the peptide product dissociates last. |
Enzyme purification, substrate specificity assays, stoichiometric cleavage assays, mass spectrometry of products, kinetic analysis |
The Journal of biological chemistry |
High |
457678
|
| 1977 |
Acyl-CoA:glycine N-acyltransferase from beef liver is composed of a single polypeptide (~35 kDa) with one active site per molecule, as demonstrated by photoaffinity labeling with p-azidobenzoyl-CoA. Benzoyl-CoA protects the enzyme from photoinactivation, confirming that p-azidobenzoyl-CoA targets the acyl-CoA binding active site. |
Photoaffinity labeling, UV irradiation, competitive protection assay with benzoyl-CoA |
Biochemistry |
High |
889778
|
| 1986 |
Acyl-CoA:glycine N-acyltransferase is exclusively an intramitochondrial enzyme in rat liver; no activity was detected in peroxisomes despite their capacity to produce acyl-CoAs. |
Subcellular fractionation, organelle-specific enzyme activity assays |
Biochemical medicine and metabolic biology |
Medium |
3741707
|
| 1994 |
Human mitochondrial acyl-CoA:glycine N-acyltransferase (ACGNAT) was purified to homogeneity from adult liver; it is a monomer of 30 kDa (pI 6.8). Km values for benzoyl-CoA, salicyl-CoA, isovaleryl-CoA, and octanoyl-CoA were determined, establishing the enzyme's substrate preference profile. |
Protein purification to homogeneity, SDS-PAGE, isoelectric focusing, enzyme kinetics |
Biochemical and biophysical research communications |
High |
7802672
|
| 1996 |
N-fatty acylglycines are enzymatically produced from fatty acyl-CoA and glycine by acyl-CoA:glycine N-acyltransferase, and N-myristoylglycine is a substrate for peptidylglycine alpha-amidating enzyme, establishing a two-enzyme biosynthetic route to fatty acid primary amides. |
In vitro enzyme assay with N-myristoylglycine substrate, measurement of (V/K)app |
Archives of biochemistry and biophysics |
Medium |
8660675
|
| 2011 |
The catalytic glutamate residue (Glu226 in bovine GLYAT) was identified as essential for activity: an E226Q mutant showed decreased activity at pH 8.0 that could be compensated by increasing pH, indicating Glu226 deprotonates glycine to facilitate nucleophilic attack on the acyl-CoA. |
Recombinant expression, E226Q active-site mutagenesis, enzyme kinetics at varying pH, protein modeling |
Drug metabolism and disposition |
High |
22071172
|
| 2012 |
Single nucleotide polymorphisms in human GLYAT alter enzyme activity: N156S variant is more active, F168L is less active, and R199C is completely inactive. An E227Q active-site mutant is also inactive, confirming Glu227 as the catalytic residue in human GLYAT. The R199C inactivity is attributed to destabilization of an α-loop-α motif important for substrate binding in the GNAT superfamily. |
Site-directed mutagenesis of recombinant human GLYAT, expression, purification, enzymatic characterization, molecular modeling with CoA |
Gene |
High |
23237781
|
| 2012 |
Human GLYAT is expressed specifically in liver and kidney, and the protein localizes to mitochondria, as confirmed by immunolabeling. |
Tissue-specific expression analysis, cellular immunolocalization with affinity-purified anti-GLYAT antibody |
Biochemical and biophysical research communications |
Medium |
22475485
|
| 2017 |
Human GLYAT exhibits mechanistic kinetic cooperativity (sigmoidal substrate activation with glycine variable and substrate inhibition with benzoyl-CoA variable) consistent with a Ferdinand enzyme mechanism, rather than the previously assumed Michaelis-Menten or ping-pong mechanism. |
Bi-substrate kinetic analysis by colorimetric and HPLC-ESI-MS/MS methods, allosteric sigmoidal enzyme kinetic modeling |
Journal of biochemical and molecular toxicology |
Medium |
28759163
|
| 2021 |
Human GLYAT wild-type protein localizes to the mitochondrial matrix when expressed as an eGFP fusion in HEK293 cells, confirming its intramitochondrial localization in a human cellular context. The p.(Gln61Leu) variant shows decreased specific activity and the p.(Asn156Ser) variant shows somewhat increased activity compared to wild-type. |
Recombinant expression in E. coli and HEK293 cells, eGFP fusion localization imaging, enzyme activity assay after purification |
Biochimie |
Medium |
33567294
|
| 2021 |
GLYAT exhibits cooperative substrate binding (two-substrate Hill kinetics) and the rare 156Asn>Ser,199Arg>Cys haplotype reduces kcat to ~9.8% of the most abundant haplotype while increasing affinity for benzoyl-CoA, demonstrating that Arg199 is critical for catalytic turnover. |
Recombinant expression of haplotype variants, kinetic characterization fitted to two-substrate Hill equation |
International journal of molecular sciences |
Medium |
33803916
|
| 2025 |
The first crystal structure of bovine GLYAT was solved in apo form and bound to benzoyl-CoA. Structural analysis and mutagenesis of key residues revealed that catalysis proceeds via a general base mechanism driven by a potential low-barrier hydrogen bond (LBHB) formed between a catalytic Glu-His dyad, with Glu deprotonating the glycine amine for nucleophilic attack on the acyl-CoA thioester. |
X-ray crystallography (apo and benzoyl-CoA-bound structures), active-site mutagenesis, functional validation |
Biochemistry |
High |
40938199
|
| 2025 |
GLYAT is upregulated in dorsal root ganglion (DRG) neurons in a mouse osteoarthritis pain model. GLYAT overexpression increases reactive oxygen species (ROS) levels in DRG neurons and upregulates TRPV1, causing mechanical and thermal hyperalgesia; GLYAT loss-of-function alleviates pain-like behaviors. ROS clearance or TRPV1 blockade in GLYAT-overexpressing mice rescues hyperalgesia, placing GLYAT upstream of ROS→TRPV1 in pain signaling. |
Transcriptomic sequencing of DRG, viral overexpression and genetic knockout in mice, ROS measurement, TRPV1 immunolabeling, pharmacological rescue with ROS scavenger and TRPV1 blocker, behavioral nociception assays |
The journal of pain |
Medium |
40288509
|
| 2025 |
A homozygous nonsense variant (p.Q108Ter) in human GLYAT abolishes GLYAT enzymatic activity in vitro, causing glycine N-acyltransferase deficiency associated with developmental delays, confirming that GLYAT enzymatic activity is required for normal glycine conjugation metabolism in humans. |
Whole exome sequencing, Sanger confirmation, in vitro activity assay of the nonsense variant |
JIMD reports |
Medium |
40747359
|